{"id":"ag-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Mucositis"}]},"_chembl":{"chemblId":"CHEMBL5306641","moleculeType":null,"molecularWeight":"663.90"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The AG regimen combines doxorubicin, a topoisomerase II inhibitor that intercalates DNA and prevents strand separation, with gemcitabine, a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA to cause chain termination. Together, these agents work synergistically to damage cancer cell DNA and trigger apoptotic pathways.","oneSentence":"AG chemotherapy is a chemotherapeutic regimen combining doxorubicin and gemcitabine to inhibit cancer cell proliferation and induce apoptosis.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:00:09.693Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication not publicly detailed; Phase 3 trial ongoing at Zhejiang Cancer Hospital)"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07475234","phase":"PHASE1, PHASE2","title":"Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Xiuchao Wang","startDate":"2026-03","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT07415525","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-01","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07408505","phase":"NA","title":"Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2026-01-20","conditions":"Advanced Pancreatic Ductal Adenocarcinoma, Cancer Anorexia-Cachexia Syndrome","enrollment":56},{"nctId":"NCT07240766","phase":"PHASE2","title":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-15","conditions":"Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT07328802","phase":"PHASE2","title":"Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"ORR,OS,PFS","enrollment":25},{"nctId":"NCT07302841","phase":"PHASE4","title":"Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-20","conditions":"Pancreatic Cancer Non-resectable","enrollment":28},{"nctId":"NCT07229586","phase":"PHASE1, PHASE2","title":"A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2025-12-02","conditions":"Solid Tumor","enrollment":100},{"nctId":"NCT06369948","phase":"NA","title":"Quality Of Recovery After Pericapsular Nerve Group (PENG) Block For Hip Hemiarthroplasty Under Spinal Anesthesia","status":"COMPLETED","sponsor":"Fayoum University Hospital","startDate":"2024-03-01","conditions":"Hip Hemiarthroplasty","enrollment":60},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT07259590","phase":"PHASE1, PHASE2","title":"A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation","status":"RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-10-21","conditions":"Advanced Solid Tumors Cancer, PDAC, CRC (Colorectal Cancer)","enrollment":126},{"nctId":"NCT07235930","phase":"PHASE3","title":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-11-15","conditions":"Non-Resectable Pancreas Carcinoma","enrollment":292},{"nctId":"NCT07232875","phase":"PHASE3","title":"HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12","conditions":"KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting","enrollment":588},{"nctId":"NCT05468489","phase":"PHASE3","title":"To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-11-18","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT06770439","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-18","conditions":"Advanced Pancreatic Cancers","enrollment":64},{"nctId":"NCT06770452","phase":"PHASE2","title":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-03-25","conditions":"Metastatic Pancreatic Carcinoma","enrollment":32},{"nctId":"NCT07079228","phase":"PHASE3","title":"A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-09-08","conditions":"Pancreatic Cancer","enrollment":602},{"nctId":"NCT05425550","phase":"NA","title":"Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.","status":"TERMINATED","sponsor":"Palleos Healthcare GmbH","startDate":"2022-08-29","conditions":"Breast Cancer","enrollment":196},{"nctId":"NCT06204991","phase":"PHASE1","title":"To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma","status":"RECRUITING","sponsor":"Inge Marie Svane","startDate":"2025-04-01","conditions":"Melanoma Stage III, Melanoma Stage IV, Melanoma","enrollment":10},{"nctId":"NCT02185690","phase":"PHASE1","title":"A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2017-03-07","conditions":"Lungcancer","enrollment":13},{"nctId":"NCT05821556","phase":"PHASE2","title":"Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2023-06-12","conditions":"Adenocarcinoma of the Pancreas","enrollment":240},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06825546","phase":"PHASE2","title":"Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-04-01","conditions":"Advanced Pancreatic Ductal Adenocarcinoma","enrollment":70},{"nctId":"NCT06435260","phase":"PHASE2","title":"Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2024-08-01","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT06944106","phase":"PHASE2","title":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-03-28","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT05222204","phase":"PHASE2","title":"DDP ip Combined With AG in PDAC With Peritoneal Metastasis","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-05-15","conditions":"Pancreatic Neoplasm","enrollment":91},{"nctId":"NCT03750669","phase":"PHASE3","title":"Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-10-20","conditions":"Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy","enrollment":324},{"nctId":"NCT06946901","phase":"PHASE2","title":"The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-04-03","conditions":"Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Metastatic Pancreatic Cancer","enrollment":90},{"nctId":"NCT06750861","phase":"PHASE2","title":"QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02-15","conditions":"Pancreatic Adenocarcinoma","enrollment":30},{"nctId":"NCT04507555","phase":"NA","title":"Pharmacist Guided Pre-emptive Pharmacogenetic Testing in Antidepressant Therapy","status":"RECRUITING","sponsor":"PD Dr. med. Thorsten Mikoteit","startDate":"2020-09-15","conditions":"Depression","enrollment":190},{"nctId":"NCT05859750","phase":"PHASE2","title":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-05-25","conditions":"Pancreatic Cancer","enrollment":78},{"nctId":"NCT06662669","phase":"PHASE1, PHASE2","title":"YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","startDate":"2024-11-30","conditions":"Metastatic Pancreatic Cancer","enrollment":120},{"nctId":"NCT06573398","phase":"PHASE2","title":"Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-09-01","conditions":"Carcinoma, Pancreatic Ductal","enrollment":20},{"nctId":"NCT06454448","phase":"PHASE1, PHASE2","title":"Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-15","conditions":"Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer","enrollment":20},{"nctId":"NCT05832892","phase":"PHASE1, PHASE2","title":"Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-11-01","conditions":"Unresectable Locally Advanced or Metastatic Pancreatic Cancer","enrollment":41},{"nctId":"NCT06404840","phase":"PHASE2","title":"Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-05-06","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT06388746","phase":"NA","title":"Arresting Carious Lesions With Minimal Intervention Techniques","status":"NOT_YET_RECRUITING","sponsor":"National and Kapodistrian University of Athens","startDate":"2024-06","conditions":"Caries,Dental","enrollment":50},{"nctId":"NCT06379438","phase":"NA","title":"Treatment of Aphtous Ulcers With Photodynamic Therapy","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2018-03-05","conditions":"Oral Ulcer, Aphthous Recurrent Ulcers","enrollment":30},{"nctId":"NCT06378580","phase":"","title":"The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma","status":"COMPLETED","sponsor":"Luo Cong","startDate":"2022-07-01","conditions":"Pancreatic Cancer","enrollment":72},{"nctId":"NCT06346808","phase":"PHASE1","title":"Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2024-05-01","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT06345599","phase":"PHASE1, PHASE2","title":"PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-05-01","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":66},{"nctId":"NCT06331442","phase":"NA","title":"The Effect of Photodynamic Therapy on Plaque in Orthodontic Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Zagreb","startDate":"2024-05","conditions":"Plaque, Dental, Dental Plaque Induced Gingivitis, White Spot Lesion","enrollment":50},{"nctId":"NCT04151277","phase":"PHASE2","title":"PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer","status":"UNKNOWN","sponsor":"Judith Dixon-Hughes","startDate":"2017-11-28","conditions":"Neoplasms Pancreatic","enrollment":500},{"nctId":"NCT06217354","phase":"PHASE1, PHASE2","title":"Efficacy of Carbetocin in Prevention of Postpartum Hemorrhage in Obese Versus Non Obese Women","status":"COMPLETED","sponsor":"Cairo University","startDate":"2023-07-06","conditions":"Obesity, Maternal, Post Partum Hemorrhage","enrollment":150},{"nctId":"NCT06166589","phase":"PHASE2","title":"Second-line Zimberelimab and SIRIOX Chemotherapy for Patient With Previously AG Chemotherapy Treated Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-01-01","conditions":"Previously AG Chemotherapy Treated Pancreatic Cancer","enrollment":19},{"nctId":"NCT06140082","phase":"","title":"Study on the Association of GSTP1 and Other Gene Polymorphisms With Platinum-induced Myelosuppression","status":"UNKNOWN","sponsor":"LI YAN","startDate":"2023-12-01","conditions":"Non-small Cell Lung Cancer","enrollment":477},{"nctId":"NCT06080854","phase":"PHASE2","title":"AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-11-10","conditions":"Pancreatic Carcinoma","enrollment":108},{"nctId":"NCT06051851","phase":"PHASE2","title":"Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2023-07-01","conditions":"Pancreatic Adenocarcinoma Metastatic","enrollment":177},{"nctId":"NCT05869474","phase":"NA","title":"Implantation of iodine125-Seeds Combined With Chemotherapy in the Treatment of Metastatic Pancreatic Carcinoma","status":"RECRUITING","sponsor":"Changhai Hospital","startDate":"2023-08-01","conditions":"Metastatic Pancreatic Cancer","enrollment":206},{"nctId":"NCT01968213","phase":"PHASE3","title":"Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2014-04-07","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":564},{"nctId":"NCT02855944","phase":"PHASE3","title":"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2017-03-01","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":349},{"nctId":"NCT03850171","phase":"NA","title":"Cancer Adverse Effects PReventIon With Care & Exercise: the CAPRICE Study","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2019-05-01","conditions":"Breast Neoplasm Female, Lymphoma, Cardiotoxicity","enrollment":57},{"nctId":"NCT04787029","phase":"NA","title":"Effect of Prophylactic Medical Compression Therapy on the Reduction of Breast Cancer-related Lymphedema in Patients With Adjuvant Docetaxel Chemotherapy: a Randomized Controlled Study","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2021-03-12","conditions":"Breast Cancer Lymphedema","enrollment":150},{"nctId":"NCT04176952","phase":"PHASE2","title":"PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Judith Dixon-Hughes","startDate":"2019-03-05","conditions":"Neoplasms Pancreatic","enrollment":31},{"nctId":"NCT05298020","phase":"PHASE2","title":"Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2022-04-01","conditions":"Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT04617821","phase":"PHASE3","title":"AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-09-01","conditions":"Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma","enrollment":300},{"nctId":"NCT00000822","phase":"PHASE1","title":"A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":46},{"nctId":"NCT04137640","phase":"PHASE4","title":"Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2021-07-19","conditions":"Breast Cancer","enrollment":152},{"nctId":"NCT02689869","phase":"PHASE2","title":"Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma","status":"UNKNOWN","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2016-04","conditions":"Indolent Non-Hodgkin Lymphoma","enrollment":98},{"nctId":"NCT04429139","phase":"NA","title":"Photodynamic Therapy With Visudyne for Human Retinoblastoma: A Preliminary Study","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-02-01","conditions":"Retinoblastoma","enrollment":8},{"nctId":"NCT03092791","phase":"PHASE1, PHASE2","title":"IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults","status":"TERMINATED","sponsor":"Takeda","startDate":"2017-06-07","conditions":"Poliomyelitis","enrollment":340},{"nctId":"NCT04101929","phase":"PHASE2","title":"Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-10-01","conditions":"Metastatic Pancreatic Cancer","enrollment":126},{"nctId":"NCT03633734","phase":"PHASE1, PHASE2","title":"Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2018-07-01","conditions":"Pancreatic Adenocarcinoma Metastatic, Chemotherapy Effect","enrollment":49},{"nctId":"NCT00711958","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-11","conditions":"Anemia","enrollment":114},{"nctId":"NCT01471873","phase":"","title":"Variability of Pentacam-derived Back Elevation Measurements in Keratoconus and Cross-linked Corneas","status":"COMPLETED","sponsor":"Democritus University of Thrace","startDate":"2011-03","conditions":"Keratoconus","enrollment":67},{"nctId":"NCT01527721","phase":"NA","title":"Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus","status":"COMPLETED","sponsor":"Democritus University of Thrace","startDate":"2010-09","conditions":"Keratoconus","enrollment":32},{"nctId":"NCT00014534","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Bladder Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2004-03","conditions":"Bladder Cancer","enrollment":42},{"nctId":"NCT02215837","phase":"PHASE2","title":"Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer","status":"UNKNOWN","sponsor":"Shenzhen Hornetcorn Bio-technology Company, LTD","startDate":"2014-08","conditions":"Gastric Cancer, Neoplasms, Gastrointestinal Neoplasms","enrollment":40},{"nctId":"NCT00108069","phase":"PHASE2","title":"Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-04","conditions":"Glioma","enrollment":43},{"nctId":"NCT00667394","phase":"PHASE2","title":"Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-04","conditions":"Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma","enrollment":42},{"nctId":"NCT00271609","phase":"PHASE2","title":"Bevacizumab for Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-12","conditions":"Recurrent High-Grade Gliomas, Malignant Gliomas","enrollment":88},{"nctId":"NCT00003105","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1997-09","conditions":"Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter","enrollment":30},{"nctId":"NCT01527708","phase":"","title":"Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas","status":"COMPLETED","sponsor":"Democritus University of Thrace","startDate":"2011-09","conditions":"Keratoconus","enrollment":129},{"nctId":"NCT01342159","phase":"NA","title":"Intravitreal Bevacizumab and Triamcinolone in Diabetic Macular Edema","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2009-03","conditions":"Diabetic Macular Edema","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AG chemotherapy","genericName":"AG chemotherapy","companyName":"Zhejiang Cancer Hospital","companyId":"zhejiang-cancer-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AG chemotherapy is a chemotherapeutic regimen combining doxorubicin and gemcitabine to inhibit cancer cell proliferation and induce apoptosis. Used for Cancer (specific indication not publicly detailed; Phase 3 trial ongoing at Zhejiang Cancer Hospital).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}